Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Revenue of Third Harmonic Bio, Inc. (THRD)
Revenue in 2023 (TTM): $
According to Third Harmonic Bio, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Third Harmonic Bio, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-35,000 | $-30,789,000 | $-30,824,000 | $-30,824,000 |
| 2022 | $ | $-38,000 | $-35,117,000 | $-35,155,000 | $-37,708,000 |
| 2021 | $ | $ | $-10,605,000 | $-29,609,000 | $-29,609,000 |
| 2020 | $ | $ | $-1,688,000 | $-12,808,000 | $-12,807,000 |